<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJRA</journal-id><journal-title-group><journal-title>Open Journal of Rheumatology and Autoimmune Diseases</journal-title></journal-title-group><issn pub-type="epub">2163-9914</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojra.2021.111001</article-id><article-id pub-id-type="publisher-id">OJRA-106990</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Profile of Juvenile Idiopathic Arthritis in Guinea
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kaba</surname><given-names>Condé</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mamadou</surname><given-names>Ciré Barry</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Carlos</surname><given-names>Othon Guelngar</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Igue</surname><given-names>Kadidjatou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mamadou</surname><given-names>Hady</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Karinka</surname><given-names>Diawara</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Konaté</surname><given-names>Mamady</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Touré</surname><given-names>Moriba</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>D.</surname><given-names>Granga D</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Awada</surname><given-names>Mohamed</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fodé</surname><given-names>Abass Cissé</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>Department of Pediatric, Mother and Child Hospital, Ndjamena, Chad</addr-line></aff><aff id="aff3"><addr-line>Department of Rheumatology, Academic Hospital, University of Conakry, Conakry, Guinea</addr-line></aff><aff id="aff2"><addr-line>Department of Pediatric, Academic Hospital, University of Conakry, Conakry, Guinea</addr-line></aff><aff id="aff1"><addr-line>Department of Neurology, Academic Hospital, University of Conakry, Conakry, Guinea</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>1</fpage><lpage>8</lpage><history><date date-type="received"><day>4,</day>	<month>November</month>	<year>2020</year></date><date date-type="rev-recd"><day>29,</day>	<month>January</month>	<year>2021</year>	</date><date date-type="accepted"><day>2,</day>	<month>February</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   Introduction: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatoid disease in children. In Sub-Saharan Africa, little data is available on the prevalence of JIA. The objective of our study was to determine the frequency and describe the clinical profile of JIA in Guinean children seen at the Department of Neurology, Academic Hospital, University of Conakry (Guinea). Patients and Method: This was a retrospective study carried out at the Ignace Deen Academic Hospital, Conakry between January 2016 and December 2018. Patients were recruited through the Rheumatology and Paediatrics Department. Results: We collected forty (40) observations of JIA in 22 girls (55%) and 18 boys (45%). The median age at diagnosis was 14 years (range 7 - 18 years), compared to 7 years at onset (range 5 and 13 years). There were 3 cases of systemic arthritis (7.5%), 16 (40%) patients with persistent oligoarthritis, 3 patients (7.5%) that had extensive oligoarthritis, polyarthritis with positive RF in 8 cases (20%) and with negative RF in 4 cases (10%), psoriatic arthritis in 3 cases (7.5%), and enthesitis related arthritis in 2 cases (5%). There was one case of undifferentiated arthritis. A total of 23 (57.5%) received methotrexate, 9 (22.5%) were treated with salazopyrin. Conclusion: The profile of JIA in our study is different from that described in African studies with a predominance of oligoarticular JIA. 
  
 
</p></abstract><kwd-group><kwd>JIA</kwd><kwd> Clinical Forms</kwd><kwd> Guinea</kwd><kwd> SSA</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Juvenile idiopathic arthritis encompasses a heterogeneous group of chronic inflammatory arthritis of unknown etiology, appearing before the 16<sup>th</sup> birthday and persisting for at least six weeks [<xref ref-type="bibr" rid="scirp.106990-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref3">3</xref>], Although onset occurs in childhood, a significant proportion of patients with JIA have active disease that persists into adulthood [<xref ref-type="bibr" rid="scirp.106990-ref4">4</xref>]. The terminology used for juvenile arthritis has evolved over time; the criteria of the International League of Associations for Rheumatology (ILAR) [<xref ref-type="bibr" rid="scirp.106990-ref5">5</xref>] include seven different subtypes: the systemic form, formerly known as Still’s disease in children, the persistent or extensive oligoarticular form, polyarticular form with negative rheumatoid factors, polyarticular form with positive rheumatoid factors, psoriatic form, enthesitis related arthritis, and undifferentiated arthritis. JIA is an important short and long-term cause of disability in children with impaired quality of life [<xref ref-type="bibr" rid="scirp.106990-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref7">7</xref>]. The epidemiological studies carried out in the framework of the JIA have been limited due to the modification of the criteria, the methodology used, and the populations studied. Despite little consensus, incidence estimates ranged from 1.6 to 23 per 100,000 and the prevalence from 3.8 to 400 per 100,000 children in the general population of North America and Europe [<xref ref-type="bibr" rid="scirp.106990-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref11">11</xref>]. In Sub-Saharan Africa, little data is available on the prevalence of JIA [<xref ref-type="bibr" rid="scirp.106990-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref13">13</xref>]. The studies carried out have focused on short series and one-off observations [<xref ref-type="bibr" rid="scirp.106990-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref14">14</xref>].</p><p>The objective of our study was to determine the frequency and describe the clinical profile of JIA in Guinean children seen at Ignace Deen Academic Hospital, Conakry, the Republic of Guinea in West Africa.</p></sec><sec id="s2"><title>2. Patients and Method</title><p>This was a retrospective study carried out at Ignace Deen Academic Hospital between January 2016 and December 2018.</p><p>Patients were recruited through the Rheumatology and Pediatrics department. The diagnosis of JIA was made in accordance with the classification criteria of the International Rheumatism League [<xref ref-type="bibr" rid="scirp.106990-ref5">5</xref>] include seven different subtypes: the systemic form or Still’s disease in children, the persistent or extended oligo-articular form, the polyarticular form with negative rheumatoid factors, the polyarticular form with positive rheumatoid factors, the psoriatic form, the enthesitic form, and the undifferentiated form.</p><p>After identifying eligible patients, the files were analysed to collect the following data: demographic (age, sex), JIA subtypes, the presence or not of uveitis, a laboratory finding including the C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), antinuclear antibodies (ANA), rheumatoid factors (RF), HLA-B27 phenotyping (human leukocyte antigen B-27). ANA was performed routinely in all patients presenting with oligoarthritis, RF in children with polyarthritis, and HLA-B27 in those with enthesitis related arthritis. The blood samples for ANA and HLA-B27 testing were conducted overseas.</p><p>A Childhood Health Assessment Questionnaire (CHAQ) was completed by parents or by children when they were able. They were sometimes helped by a doctor and/or a nurse. A visual analogue scale (VAS) from 0 to 100 was used to assess the intensity of pain and general well-being on nonsteroidal anti-inflammatory drugs (NSAIDs), oral corticosteroid therapy, or corticosteroid infiltration, methotrexate and salazopyrin.</p><p>All study procedures were explained in detail to parents and patients. All parents and, if possible, capable children (over the age of 16) signed consent forms before being included in the study. It was clearly explained that if patients did not wish to participate in the study, it would not affect the quality of their care.</p></sec><sec id="s3"><title>3. Results</title>Socio-Demographic Aspect<p>During the study period, we collected forty (40) observations of JIA in 22 girls (55%) and 18 boys (45%). The mean age at diagnosis was 14 years (range 7 - 18 years), while it was 7 years at onset (range 5 and 13 years) (<xref ref-type="table" rid="table1">Table 1</xref>). There were 3 cases of systemic JIA (7.5%), 16 (40%) patients with persistent oligoarthritis, 3 patients (7.5%) had extensive oligoarthritis, polyarthritis with RF positive in 8 cases (20%) and with negative RF in 4 cases (10%), psoriatic arthritis in 3 cases (7.5%), and enthesitis related arthritis in 2 cases (5%). There was one case of undifferentiated arthritis. Uveitis was present in 11 cases (5 cases in the persistent oligoarticular forms and 2 cases in the extensive forms). The mean value of ESR, CRP, VAS, and CHAQ for each clinical form is shown in <xref ref-type="table" rid="table1">Table 1</xref>.</p><p>Twenty-two patients tested for ANA. Ten were ANA positive (persistent oligoarthritis 7 cases, and extensive 2 cases). Two patients were HLA-B27 positive and all had an enthesitis related arthritis. A total of 23 (57.5%) received methotrexate, 9 (22.5%) were treated with salazopyrin. NSAIDs were used in 13 cases (32.5%), oral corticosteroids 12 (30%) and corticosteroid infiltrations in 6 cases (15%).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Socio-demographic, clinical, paraclinical and evolutionary characteristics of JIA</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Types of JIA</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >%</th><th align="center" valign="middle" >Girls</th><th align="center" valign="middle" >Average age at the beginning</th><th align="center" valign="middle" >Average age Current</th><th align="center" valign="middle" >VS</th><th align="center" valign="middle" >CRP</th><th align="center" valign="middle" >Uveitis</th><th align="center" valign="middle" >CHAQ</th><th align="center" valign="middle" >General VAS</th><th align="center" valign="middle" >General VAS pain</th></tr></thead><tr><td align="center" valign="middle" >Systemic</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >7.50%</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.01</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >60</td></tr><tr><td align="center" valign="middle" >Poly RF+</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >20%</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >16.25</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >80</td></tr><tr><td align="center" valign="middle" >Poly RF−</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >10%</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.5</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >70</td></tr><tr><td align="center" valign="middle" >Persistent oligo</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >40%</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >70</td></tr><tr><td align="center" valign="middle" >Extensive oligo</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >7.50%</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.9</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >70</td></tr><tr><td align="center" valign="middle" >Psoriasis</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >7.50%</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.6</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >40</td></tr><tr><td align="center" valign="middle" >Enthesic</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >5%</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.4</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >50</td></tr><tr><td align="center" valign="middle" >Undifferentiated</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.50%</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.7</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >50</td></tr></tbody></table></table-wrap><p>JIA: Juvenile Idiopathic Arthritis; Poly: polyarthritis; Oligo: oligoarthritis; RF+: positive rheumatoid factors; RF−: negative rheumatoid factors: PCR: protein c reactive; SR: sedimentation rate; CHAQ: Childhood Health Assessment Questionnaire; VAS: visual analog scale, n: number.</p></sec><sec id="s4"><title>4. Discussion</title><p>In our study, the profile of JIA is different from other studies carried out in Sub-Saharan Africa, Morocco and elsewhere in the world [<xref ref-type="bibr" rid="scirp.106990-ref12">12</xref>] - [<xref ref-type="bibr" rid="scirp.106990-ref17">17</xref>] (<xref ref-type="table" rid="table2">Table 2</xref>). However, the different methodologies used by these studies constitute a limit to this comparison. The mean age at diagnosis in our study (8 years) was identical to that of Senegal [<xref ref-type="bibr" rid="scirp.106990-ref12">12</xref>], South Africa [<xref ref-type="bibr" rid="scirp.106990-ref13">13</xref>] and higher than that of Turkey [<xref ref-type="bibr" rid="scirp.106990-ref16">16</xref>], Morocco [<xref ref-type="bibr" rid="scirp.106990-ref15">15</xref>] and Western Europe [<xref ref-type="bibr" rid="scirp.106990-ref17">17</xref>]. This average age is due to the delay in diagnosis and the lack of a centre specializing in the management of pathologies in children in SSA. In our study, we noted a female predominance as described in Western populations [<xref ref-type="bibr" rid="scirp.106990-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref19">19</xref>].</p><p>Oligoarthritis</p><p>In our study, oligoarticular JIA were the most common among JIA subtypes (persistent oligoarthritis 40%, extensive oligoarthritis 7.5%). This result is in agreement with the series described in Western populations where oligoarticular forms are the most frequent [<xref ref-type="bibr" rid="scirp.106990-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref20">20</xref>]. This high frequency of oligoarticular forms is an interesting finding in our study, as they are considered to be less frequent in non-Europeans [<xref ref-type="bibr" rid="scirp.106990-ref20">20</xref>].</p><p>Polyarthritis</p><p>In the studies compared in <xref ref-type="table" rid="table2">Table 2</xref>, our results show the second highest rate</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of our study with data from African and western literature</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Study</th><th align="center" valign="middle" >Senegal [<xref ref-type="bibr" rid="scirp.106990-ref12">12</xref>]</th><th align="center" valign="middle" >South [<xref ref-type="bibr" rid="scirp.106990-ref13">13</xref>] Africa</th><th align="center" valign="middle" >Zambia [<xref ref-type="bibr" rid="scirp.106990-ref14">14</xref>]</th><th align="center" valign="middle" >Morocco [<xref ref-type="bibr" rid="scirp.106990-ref15">15</xref>]</th><th align="center" valign="middle" >Turkey [<xref ref-type="bibr" rid="scirp.106990-ref16">16</xref>]</th><th align="center" valign="middle" >Printo [<xref ref-type="bibr" rid="scirp.106990-ref17">17</xref>] W, Europe</th><th align="center" valign="middle" >Guinea</th></tr></thead><tr><td align="center" valign="middle" >n</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >196</td><td align="center" valign="middle" >2102</td><td align="center" valign="middle" >40</td></tr><tr><td align="center" valign="middle" >Women (%)</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >83</td><td align="center" valign="middle" >55</td></tr><tr><td align="center" valign="middle" >Average age at diagnosis (years)</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >8.7</td><td align="center" valign="middle" >7.53</td><td align="center" valign="middle" >7.0</td><td align="center" valign="middle" >5.4</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >Current average age (years)</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >10.85</td><td align="center" valign="middle" >8.8</td><td align="center" valign="middle" >9.4</td><td align="center" valign="middle" >15</td></tr><tr><td align="center" valign="middle" >Systemic (%)</td><td align="center" valign="middle" >6.6</td><td align="center" valign="middle" >7.69</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >15.3</td><td align="center" valign="middle" >16.4</td><td align="center" valign="middle" >7.5</td></tr><tr><td align="center" valign="middle" >Polyarthrite (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >40.9</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >31.5</td><td align="center" valign="middle" >37.2</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Polyarthritis RF+ (%)</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >14.1</td><td align="center" valign="middle" >11.5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >6.6</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >20</td></tr><tr><td align="center" valign="middle" >Polyarthritis RF− (%)</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >26.9</td><td align="center" valign="middle" >34.6</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >30.6</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle" >Persistent oligoarthritis (%)</td><td align="center" valign="middle" >6.66</td><td align="center" valign="middle" >21.79</td><td align="center" valign="middle" >32.1</td><td align="center" valign="middle" >37.5</td><td align="center" valign="middle" >24.4</td><td align="center" valign="middle" >29.5</td><td align="center" valign="middle" >40</td></tr><tr><td align="center" valign="middle" >Extensive oligoarthritis (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >5.12</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >9.6</td><td align="center" valign="middle" >21.5</td><td align="center" valign="middle" >7.5</td></tr><tr><td align="center" valign="middle" >Psoriasis (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.2</td><td align="center" valign="middle" >1.3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >7.5</td></tr><tr><td align="center" valign="middle" >Enthesic (%)</td><td align="center" valign="middle" >26.6</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >6.4</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >10.3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >5</td></tr><tr><td align="center" valign="middle" >Undifferentiated (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.5</td></tr><tr><td align="center" valign="middle" >VS average</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >25.1</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >30.7</td><td align="center" valign="middle" >26</td></tr><tr><td align="center" valign="middle" >CHAQ</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.73</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.84</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.7</td><td align="center" valign="middle" >0.6</td></tr><tr><td align="center" valign="middle" >VAS pain</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >28</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >20</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >40</td></tr><tr><td align="center" valign="middle" >General VAS</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >25</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >50</td></tr></tbody></table></table-wrap><p>SR: sedimentation rate; CHAQ: Childhood Health Assessment Questionnaire; VAS: visual analog scale; n: number.</p><p>of rheumatoid factor positive arthritis (20%) and the lowest rate for rheumatoid factor negative arthritis (10%). Its forms were the most disabling with a significant deterioration in the quality of life (<xref ref-type="fig" rid="fig1">Figure 1</xref>). These results are in contrast to previous studies carried out in African populations which showed a higher risk of the polyarthritis subtype among JIA [<xref ref-type="bibr" rid="scirp.106990-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref21">21</xref>].</p><p>Systemic JIA (sJIA)</p><p>Current data show that sJIA are less frequent in SSA [<xref ref-type="bibr" rid="scirp.106990-ref21">21</xref>], however short series have been reported in Senegal [<xref ref-type="bibr" rid="scirp.106990-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref22">22</xref>] and Ivory Coast [<xref ref-type="bibr" rid="scirp.106990-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref24">24</xref>]. These forms are undoubtedly underestimated due to the weakness of the technical laboratory and specialised centres to make the differential diagnosis.</p><p>Enthesitis related arthritis</p><p>The frequency of arthritis linked to enthesitis in our study is the lowest (5%) compared to the studies cited in <xref ref-type="table" rid="table2">Table 2</xref>. This result is in agreement with the data in the literature, in fact, enthesitis is rarely associated with juvenile arthritis in African populations [<xref ref-type="bibr" rid="scirp.106990-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref20">20</xref>]. It has been described as being the most common form in Asians and Indians [<xref ref-type="bibr" rid="scirp.106990-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref24">24</xref>].</p><p>Psoriatic forms and undifferentiated forms were less frequent in 1 and 2 cases, respectively. This trend has been found in Senegal, and in South Africa [<xref ref-type="bibr" rid="scirp.106990-ref13">13</xref>].</p><p>In agreement with the data in the literature [<xref ref-type="bibr" rid="scirp.106990-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref27">27</xref>], the extra-articular manifestations were dominated by uveitis in 27.5% of cases and were mainly</p><p>found in the oligoarticular JIA. A number of risk factors for JIA-uveitis have been identified [<xref ref-type="bibr" rid="scirp.106990-ref28">28</xref>]. Younger age, female sex, oligoarticular form, and the presence of ANA are risk factors for chronic anterior uveitis. On the other hand, the male sex with positive HAL-B27 is a risk factor for acute anterior uveitis [<xref ref-type="bibr" rid="scirp.106990-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.106990-ref32">32</xref>].</p><p>The limitations of our study were the size of the sample, the difficulty in performing the immunoassay (ANA, HLA-B27). The lack of resources in pediatric rheumatology and hospitals dedicated to the care of children. However, this is one of the biggest AJI series in sub-Saharan Africa</p></sec><sec id="s5"><title>5. Conclusion</title><p>Oligo articular forms were the most frequent in our study (47.5%). A female predominance was noted and JIA was associated with uveitis in 27.5% of cases. The establishment of a sub-regional register is necessary to better characterize the AJIs in black Africa.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Cond&#233;, K., Barry, M.C., Guelngar, C.O., Kadidjatou, I., Hady, M., Diawara, K., Mamady, K., Moriba, T., Granga D, D., Mohamed, A. and Ciss&#233;, F.A. (2021) Profile of Juvenile Idiopathic Arthritis in Guinea. Open Journal of Rheumatology and Autoimmune Diseases, 11, 1-8. https://doi.org/10.4236/ojra.2021.111001</p></sec></body><back><ref-list><title>References</title><ref id="scirp.106990-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Moradi, A., Amin, R.M. and Thorne, J.E. (2014) The Role of Gender in Juvenile Idiopathic Arthritis-Associated Uveitis. Journal of Ophthalmology, 2014, Article ID: 461078. https://doi.org/10.1155/2014/461078</mixed-citation></ref><ref id="scirp.106990-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Heiligenhaus, A., Heinz, C., Edelsten, C., Kotaniemi, K. and Minden, K. (2013) Review for Disease of the Year: Epidemiology of Juvenile Idiopathic Arthritis and Its Associated Uveitis: The Probable Risk Factors. Ocular Immunology and Inflammation, 21, 180-191. https://doi.org/10.3109/09273948.2013.791701</mixed-citation></ref><ref id="scirp.106990-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Qian, Y. and Acharya, N.R. (2010) Juvenile Idiopathic Arthritis-Associated Uveitis. Current Opinion in Ophthalmology, 21, 468-472. https://doi.org/10.1097/ICU.0b013e32833eab83</mixed-citation></ref><ref id="scirp.106990-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Carvounis, P.E., Herman, D.C., Cha, S. and Burke, J.P. (2006) Incidence and Outcomes of Uveitis in Juvenile Rheumatoid Arthritis, a Synthesis of the Literature. Graefe’s Archive for Clinical and Experimental Ophthalmology, 244, 281-290. https://doi.org/10.1007/s00417-005-0087-3</mixed-citation></ref><ref id="scirp.106990-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Clarke, S.L., Sen, E.S. and Ramanan, A.V. (2016) Juvenile Idiopathic Arthritis-Associated Uveitis. Pediatric Rheumatology Online Journal, 14, 27. https://doi.org/10.1186/s12969-016-0088-2</mixed-citation></ref><ref id="scirp.106990-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Choi, J., Hawley, D.P., Ashworth, J., Edelsten, C. and Bossuyt, A.S.M. (2019) An Update on the Modern Management of Paediatric Uveitis. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2019-314212</mixed-citation></ref><ref id="scirp.106990-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Barut, K., Adrovic, A., Sahin, S., Tarcin, G., Tahaoglu, G., et al. (2019) Prognosis, Complications and Treatment Response in Systemic Juvenile Idiopathic Arthritis Patients: A Single-Center Experience. International Journal of Rheumatic Diseases, 22, 1661-1669. https://doi.org/10.1111/1756-185X.13649</mixed-citation></ref><ref id="scirp.106990-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Barut, K., Adrovic, A., &amp;#350;ahin, S. and Kasap&amp;#231;opur, &amp;#214;. (2017) Juvenile Idiopathic Arthritis. Balkan Medical Journal, 34, 90. https://doi.org/10.4274/balkanmedj.2017.0111</mixed-citation></ref><ref id="scirp.106990-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Diomandé, M., Coulibaly, A.K., Kouakou, E.S.C.L., Yao, J.C., Kouakou, C. and Gbané-Koné, M. (2016) Profile of Juvenile Idiopathic Arthritis Observed in Abidjan (Cote d’Ivoire): A Report about 17 Cases. British Journal of Medicine and Medical Research, 16, 1-6. https://doi.org/10.9734/BJMMR/2016/27043</mixed-citation></ref><ref id="scirp.106990-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Diomandé, M., Coulibaly, A.K., Ngandeu, A.N., Kouakou, C., Kouakou, E.S.C.L., et al. (2017) Systemic Form of Juvenile Idiopathic Arthritis: Epidemiological, Clinical, Paraclinical and Therapeutic Aspects of 13 Cases in Abidjan. Open Journal of Rheumatology and Autoimmune Diseases, 7, 103-110. https://doi.org/10.4236/ojra.2017.72009</mixed-citation></ref><ref id="scirp.106990-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Diallo, S., Niasse, C. and Diouf, M. (2014) Still’s Disease in Adult and Child: Report of Sixteen Cases. Revue Cames Santé, 2, 29-34.</mixed-citation></ref><ref id="scirp.106990-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Schwartz, M.M., Simpson, P., Kerr, K.L., Jarvis, J.N. and Schwatrz, J. (1997) Juvenile Rheumatoid Arthritis in African Americans. The Journal of Rheumatology, 24, 1826-1829.</mixed-citation></ref><ref id="scirp.106990-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Claudia, M., Khoa, N. and Diana, M. (2009) AJI oligoarticulaire et polarticulaire: épidémiologie et pathogenèse. Nature Reviews Rheumatology, 5, 616-626. https://doi.org/10.1038/nrrheum.2009.209</mixed-citation></ref><ref id="scirp.106990-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Nordal, E., Rypdal, V., Arnstad, E., Aalto, K., Berntson, et al. (2019) Participation in School and Physical Education in Juvenile Idiopathic Arthritis in a Nordic Long-Term Cohort Study. Pediatric Rheumatology Online Journal, 15, 44. https://doi.org/10.1186/s12969-019-0341-6</mixed-citation></ref><ref id="scirp.106990-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kunjir, V., Venugopalan, A. and Chopra, A. (2010) Profile of Indian Patients with Juvenile Onset Chronic Inflammatory Joint Disease Using the ILAR Classification Criteria for JIA: A Community-Based Cohort Study. The Journal of Rheumatology, 37, 1756-1762. https://doi.org/10.3899/jrheum.090937</mixed-citation></ref><ref id="scirp.106990-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Gutierrez-Suarez, R., Pistorio, A., Cespedes Cruz, A., Norambuena, X., Flato, B., Rumba, I., Harjacek, M., et al. (2007) Health-Related Quality of Life of Patients with Juvenile Idiopathic Arthritis Coming from 3 Different Geographic Areas. The PRINTO Multinational Quality of Life Cohort Study. Rheumatology, 46, 314-320. https://doi.org/10.1093/rheumatology/kel218</mixed-citation></ref><ref id="scirp.106990-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Yilmaz, M., Kendirli, G., Altintas, D.U., Karakoc, G.B., Inal, A. and Kilic, M. (2008) Juvenile Idiopathic Arthritis Profile in Turkish Children. Pediatrics International, 50, 154-158. https://doi.org/10.1111/j.1442-200X.2008.02543.x</mixed-citation></ref><ref id="scirp.106990-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Amine, B., Rostom, S., Benbouazza, K., Abouqal, R. and Hajjaj-Hassouni, N. (2009) Health Related Quality of Life Survey about Children and Adolescents with Juvenile Idiopthic Arthritis. Rheumatology International, 29, 275-279. https://doi.org/10.1007/s00296-008-0672-y</mixed-citation></ref><ref id="scirp.106990-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Chipeta, J., Njobvu, P., Wa-Somwe, S., Chintu, C., McGill, P.E. and Bucala, R. (2013) Clinical Patterns of Juvenile Idiopathic Arthritis in Zambia. Pediatric Rheumatology Online Journal, 1, 33. https://doi.org/10.1186/1546-0096-11-33</mixed-citation></ref><ref id="scirp.106990-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Weakley, K., Esser, M. and Scott, C. (2012) Juvenile Idiopathic Arthritis in Two Tertiary Centres in the Western Cape, South Africa. Pediatric Rheumatology Online Journal, 10, 35. https://doi.org/10.1186/1546-0096-10-35</mixed-citation></ref><ref id="scirp.106990-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Diallo, S., Pouye, A., Ndongo, S., Diagne, I. and Diop, T. (2008) Arthrites juvéniles idiopathiques: étude de 30 cas Sénégalais. Revue du Rhumatisme, 75, 1136.</mixed-citation></ref><ref id="scirp.106990-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Thierry, S., Fautrel, B., Lemelle, I. and Guillemin, F. (2014) Prevalence and Incidence of Juvenile Idiopathic Arthritis: A Systematic Review. Joint Bone Spine, 81, 112-117. https://doi.org/10.1016/j.jbspin.2013.09.003</mixed-citation></ref><ref id="scirp.106990-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Abou El-Soud, A.M., El-Najjar, A.R., El-Shahawy, E.E., Amar, H.A., Hassan, T.H., et al. (2013) Prevalence of Juvenile Idiopathic Arthritis in Sharkia Governorate, Egypt: Epidemiological Study. Rheumatology International, 33, 2315-2322. https://doi.org/10.1007/s00296-013-2707-2</mixed-citation></ref><ref id="scirp.106990-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Sauremann, R.K., Rose, J.B., Tyrell, P., Alenafu, E., Doria, A.S., Stevens, D., et al. (2007) Epidemiology of Juvenile Idiopathic Arthritis in a Multiethnic Cohort: Ethnicity as a Risk Factor. Arthritis &amp; Rheumatology, 56, 1974-1984. https://doi.org/10.1002/art.22709</mixed-citation></ref><ref id="scirp.106990-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Manners, P.J. and Diepeveen, D.A. (1996) Prevalence of Juvenile Chronic Arthritis in a Population of 12 Year Old Children in Urban Australia. Pediatrics, 98, 84-90.</mixed-citation></ref><ref id="scirp.106990-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Giancane, G., Alongi, A. and Ravelli, A. (2017) Update on the Pathogenesis and Treatment of Juvenile Idiopathic Arthritis. Current Opinion in Rheumatology, 29, 523-529. https://doi.org/10.1097/BOR.0000000000000417</mixed-citation></ref><ref id="scirp.106990-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Lundberg, V. and Eriksson, C. (2017) Health-Related Quality of Life among Swedish Children with Juvenile Idiopathic Arthritis: Parent-Child Discrepancies, Gender Differences and Comparison with a European Cohort. Pediatric Rheumatology Online Journal, 15, 26. https://doi.org/10.1186/s12969-017-0153-5</mixed-citation></ref><ref id="scirp.106990-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Petty, R.E., Southwood, T.R., Manners, P., et al. (2004) International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis: Second Revision, Edmonton, 2001. The Journal of Rheumatology, 31, 390-392.</mixed-citation></ref><ref id="scirp.106990-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Selvaag, A.M., Aulie, H.A., Lilleby, V. and Flato, B. (2016) Disease Progression into Adulthood and Predictors of Long-Term Active Disease in Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 75, 190-195. https://doi.org/10.1136/annrheumdis-2014-206034</mixed-citation></ref><ref id="scirp.106990-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Prakken, B., Albani, S. and Martini, A. (2011) Juvenile Idiopathic Arthritis. The Lancet, 377, 2138-2149. https://doi.org/10.1016/S0140-6736(11)60244-4</mixed-citation></ref><ref id="scirp.106990-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Cimaz, R. (2016) Systemic-Onset Juvenile Idiopathic Arthritis. Autoimmunity Reviews, 15, 931-934. https://doi.org/10.1016/j.autrev.2016.07.004</mixed-citation></ref><ref id="scirp.106990-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Khodra, B., Stevens, A. and Ferucci, E.D. (2019) Prevalence of Juvenile Idiopathic Arthritis in the Alaska Native Population. Arthritis Care &amp; Research (Hoboken). https://doi.org/10.1002/acr.23997</mixed-citation></ref></ref-list></back></article>